PharmaEssentia announced yesterday that it has applied for market approval in Vietnam for its new drug, BESREMi (Ropeginterferon alfa-2b, also known as Ropeg or P1101), for the treatment of Polycythemia Vera (PV), marking its expansion into the Southeast Asian market.
PharmaEssentia CEO Ko-Chung Lin stated that the company is committed to addressing the urgent medical needs in the field of myeloproliferative neoplasms (MPN) by providing innovative treatment options for PV patients and continues to expand its global footprint. Ropeg is a next-generation long-acting interferon developed and manufactured by PharmaEssentia. It has already been approved in over 40 countries for the treatment of adult PV patients, including in major new drug markets such as the European Union, the United States, and Japan, with strong and sustained global sales growth.
In the Southeast Asian market, Ropeg has already received PV drug approvals in Singapore and Malaysia. The application for approval in Vietnam will further increase its influence in the region.
PharmaEssentia stated that Vietnam is one of the fastest-growing economies in Southeast Asia, with a population of over 100 million. As a key pharmaceutical market in ASEAN, Vietnam is not only a hub for Southeast Asia’s pharmaceutical industry but also faces increasing demand for high-quality healthcare. According to market research, Vietnam's pharmaceutical market has been expanding steadily in recent years, with the market size surpassing $7 billion in 2024, and is expected to continue growing at a stable rate in the coming years. The Vietnamese government is also actively promoting healthcare reforms and increasing insurance coverage, providing an excellent development opportunity for international pharmaceutical companies.
PharmaEssentia continues to invest in innovative research and development and is actively expanding its international market presence. The application for the PV drug approval in Vietnam demonstrates the company's focus on the local market.
Resource: 藥華藥新品 賣向越南
